The role of NF-kB and von Hippel-Lindau protein in the creation of a molecular portrait of kidney cancers
- Authors: Spirina L.V1,2, Slonimskaya E.M1,2, Yurmazov Z.A1, Usynin E.A1, Lushnikova N.A1, Tarasenko N.V2,3, Kondakova I.V1
-
Affiliations:
- Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
- Siberian State Medical University
- Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences
- Issue: Vol 17, No 3 (2019)
- Pages: 15-19
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2918/article/view/113087
- DOI: https://doi.org/10.29296/24999490-2019-03-03
- ID: 113087
Cite item
Abstract
Keywords
Full Text
About the authors
L. V Spirina
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University
Email: spirinalvl@mail.ru
E. M Slonimskaya
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University
Z. A Yurmazov
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
E. A Usynin
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
N. A Lushnikova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
N. V Tarasenko
Siberian State Medical University; Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences
I. V Kondakova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
References
- Спирина Л.В., Усынин Е.А., Кондакова И.В., Юрмазов З.А., Слонимская Е.М. Влияние таргетной терапии на содержание транскрипционных, ростовых факторов, протеинкиназы TOR и активности внутриклеточных протеиназ у больных диссеминированным раком почки. Бюллетень экспериментальной биологии и медицины. 2015; 160 (12): 768-72
- Спирина Л.В., Кондакова И.В., Усынин Е.А., Юрмазов З.А. Регуляция экспрессии транскрипционных факторов и фактора роста эндотелия протеасомной системой при метастазировании рака почки. Вестник РОНЦ им. Н. Н. Блохина РАМН. 2012; 23 (1): 27-32
- Спирина Л.В., Кондакова И.В., Усынин Е.А., Коломиец Л.А., Винтизенко С.И., Бочкарева Н.В., Чернышова А.Л. Активность протеасом и содержание ростовых факторов при раке почки, мочевого пузыря и эндометрия. Российский онкологический журнал. 2010; 1: 23-5
- Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., Klausner R.D., Pause A. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA. 1999; 96 (22): 12436-41
- Kroeger N., Seligson D.B., Signoretti S., Yu H., Magyar C.E., Huang J., Belldegrun A.S., Pantuck A.J. Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor 2a. Eur. J. Cancer. 2014; 50 (8): 1531-40. https://doi.org/10.1016/j.ejca.2014.01.031
- Shen C., Kaelin W.G. Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2012; 23 (1): 18-25. https://doi. org/10.1016/j.semcancer.2012.06.001
- Zhao Z., Chen C., Lin J., Zeng W., Zhao J., Liang Y, Tan Q., Yang C., Li H.Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma. Mol. Med. Rep. 2016; 14 (3): 2785-90. https://doi.org/10.3892/ mmr.2016.5561
- Razafinjatovo C.F., Stiehl D., Deininger E., Rechsteiner M., Moch H., Schraml P.VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFa degradation in clear cell renal cell carcinoma. Oncotarget. 2017; 8 (6): 10199-212. https://doi.org/10.18632/ oncotarget.14372
- Menke J., Kriegsmann J., Schimanski C.C., Schwartz M.M., Schwarting A., Kelley VR. Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Cancer Res. 2012; 72 (1): 187-200. https://doi.org/10.1158/0008-5472
- Melendez-Rodriguez F., Roche O., Sanchez-Prieto R., Aragones J. Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. Front Oncol. 2018; 8: 214. https://doi. org/10.3389/fonc.2018.00214
- Cho D.C., Mier J.W. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets. 2013; 13 (2): 126-42
- De Vivar Chevez A.R., Finke J., Bukowski R. The role of inflammation in kidney cancer, Adv Exp. Med. Biol. 2014; 816: 197-234. https://doi.org/10.1007/978-3-0348-0837-8_9
- Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49 (11): 1603-16. https://doi.org/10.1016/jtreeradbiomed.2010.09.006
- Fitzgerald J.P., Nayak B., Shanmugasundaram K., Friedrichs W., Sudarshan S., Eid A.A., DeNapoli T., Parekh D.J., Gorin Y., Block K. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8-production. PLoS ONE. 2012; 7 (1): e30712. https://doi.org/10.1371/journal. pone.0030712
- Kaelin W.G. Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. 2009; 15 (115 (10 Suppl)): 2262-72. https://doi.org/10.1002/ cncr.24232
- Johrer K., Zelle-Rieser C., Perathoner A., Moser P., Hager M., Ramoner R., Gander H., Haiti L., Bartsch G., Greil R., Thurnher M. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res. 2005; 11 (7): 2459-65. https://doi.org/10.1158/1078-0432.CCR-04-0405
- Xia Y., Shen S., Verma I.M. NF-kB, an active player in human cancers. Cancer Immunol Res. 2014; 2 (9): 823-30. https://doi. org/10.1158/2326-6066.CIR-14-0112
- Al-Sadi R., Guo S., Ye D., Rawat M., Ma T.Y. TNF-a Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/ IKK-a Axis Activation of the Canonical NF-kB Pathway. Am. J. Pathol. 2016; 186 (5): 1151-65. https://doi.org/10.10Wj. ajpath.2015.12.016
- Gupta S.C., Sundaram C., Reuter S., Aggarwal B.B. Inhibiting NF-kB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010; 1799 (10-12): 775-87. https://doi.org/10.10Wj.bba-grm.2010.05.004
- D'Ignazio L., Batie M., Rocha S. Hypoxia and Inflammation in Cancer, Focus on HIF and NF-kB. Biomedicines. 2017; 5 (2): 21. https://doi.org/10.3390/biomedi-cines5020021
- Safa A.R. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012; 34 (3): 176-84
- Zhang H., Sun S.C. NF-kB in inflammation and renal diseases Cell Biosci. 2015; 5: 63. https://doi.org/10.1186/s13578-015-0056-4
- Kim H.D., Yu S.J., Kim H.S., Kim Y.J., Choe J.M., Park Y.G., Kim J., Sohn J. Interleukin-4 induces senescence in human renal carcinoma cell lines through STAT6 and p38 MAPK. J. Biol. Chem. 2013; 288 (40): 28743-54. https://doi.org/10.1074/jbc. M113.499053
- Linehan W.M., Ricketts C.J. The metabolic basis of kidney cancer. Semin Cancer Biol. 2012; 23 (1): 46-55. https://doi. org/10.1016/j.semcancer.2012.06.002
- An H., Xu L., Zhu Y, Lv T, Liu W., Liu Y, Liu H., Chen L., Xu J., Lin Z. High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br. J. Cancer. 2014; 110 (9): 2261-8. https://doi.org/10.1038/ bjc.2014.179
- Labrousse-Arias D., Martinez-Alonso E., Corral-Escariz M., Bienes-Martinez R., Berridy J., Serrano-Oviedo L., Conde E., Garcia-Bermejo M.L., Gimenez-Bachs J.M., Salinas-Sanchez A.S., Sanchez-Prieto R., Yao M., Lasa M., Calzada M.J. VHL promotes immune response against renal cell carcinoma via NF-KB-dependent regulation of VCAM-1. J. Cell. Biol. 2017; 216 (3): 835-47. https://doi.org/10.1083/ jcb.201608024
- Asgarova A., Asgarov K., Godet Y, Peixoto P., Nadaradjane A., Boyer-Guittaut M., Galaine J., Guenat D., Mougey V, Perrard J., Pallandre J.R., Bouard A., Balland J., Tirole C., Adotevi O., Hendrick E., Herfs M., Cartron P.F., Borg C., Hervouet E. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018; 7 (5): e1423170. https:// doi.org/10.1080/2162402X.2017.1423170
- Bally A.P., Lu P., Tang Y, Austin J.W., Scharer C.D., Ahmed R., Boss J.M. NF-kB regulates PD-1 expression in macrophages. J. Immunol. 2015; 194 (9): 4545-54. https://doi. org/10.4049/jimmunol.1402550
- Makhov P., Naito S., Haifler M., Kutikov A., Boumber Y, Uzzo R.G., Kolenko V.M. The convergent roles of NF-kB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death Dis. 2018; 9 (3): 374. https://doi. org/10.1038/s41419-018-0388-1